RAJENDER APARASU to Adult
This is a "connection" page, showing publications RAJENDER APARASU has written about Adult.
Connection Strength
1.017
-
Factors associated with initial medication adherence with first-line therapy for depression. J Affect Disord. 2025 Dec 15; 391:120004.
Score: 0.055
-
Marginal health care expenditures for melanoma care in the United States. J Manag Care Spec Pharm. 2024 Dec; 30(12):1364-1374.
Score: 0.052
-
Comparative effectiveness of high-efficacy and moderate efficacy disease-modifying agents in reducing the annualized relapse rates among multiple sclerosis patients in the United States. Prev Med. 2025 Jan; 190:108180.
Score: 0.052
-
Infection Risk Associated with High-Efficacy Disease-Modifying Agents in Multiple Sclerosis: A Retrospective Cohort Study. Clin Pharmacol Ther. 2025 Feb; 117(2):561-569.
Score: 0.052
-
Factors associated with the initiation of high-efficacy disease-modifying agents over moderate-efficacy disease-modifying agents in multiple sclerosis. Mult Scler Relat Disord. 2024 Nov; 91:105896.
Score: 0.051
-
Association of oral disease-modifying agents and their adherence trajectories with annual relapses in multiple sclerosis. Mult Scler Relat Disord. 2024 May; 85:105539.
Score: 0.050
-
Real-world Comparative Effectiveness of Methotrexate-based Combinations for Rheumatoid Arthritis: A Retrospective Cohort Study. Clin Ther. 2023 09; 45(9):e177-e186.
Score: 0.048
-
Risk of incident cardiovascular events with disease-modifying anti-rheumatic drugs among adults with rheumatoid arthritis: a nested case-control study. Clin Rheumatol. 2024 Jan; 43(1):103-116.
Score: 0.048
-
Comparative adherence trajectories of oral disease-modifying agents in multiple sclerosis. Pharmacotherapy. 2023 06; 43(6):473-484.
Score: 0.047
-
Machine learning methods to predict 30-day hospital readmission outcome among US adults with pneumonia: analysis of the national readmission database. BMC Med Inform Decis Mak. 2022 11 09; 22(1):288.
Score: 0.045
-
Health-related quality of life of patients with multiple sclerosis: Analysis of ten years of national data. Mult Scler Relat Disord. 2022 Oct; 66:104019.
Score: 0.044
-
FACTORS ASSOCIATED WITH SWITCHING FROM INJECTABLE TO ORAL DISEASE MODIFYING AGENTS AMONG PATIENTS WITH MULTIPLE SCLEROSIS. Mult Scler Relat Disord. 2022 Apr; 60:103703.
Score: 0.043
-
Opioid Prescribing Among Outpatients with Rheumatoid Arthritis. Pain Med. 2021 10 08; 22(10):2224-2234.
Score: 0.042
-
Comparative treatment effectiveness of oral fingolimod and conventional injectable disease-modifying agents in multiple sclerosis. Pharmacotherapy. 2021 05; 41(5):440-450.
Score: 0.040
-
Factors Associated with Prescribing Oral Disease Modifying Agents in Multiple Sclerosis: a Real-world Analysis of Electronic Medical Records. Mult Scler Relat Disord. 2020 Oct; 45:102334.
Score: 0.038
-
Marginal Health Care Expenditure Burden Among U.S. Civilian Noninstitutionalized Individuals with Multiple Sclerosis: 2010-2015. J Manag Care Spec Pharm. 2020 Jun; 26(6):741-749.
Score: 0.038
-
Quality of life of patients with Parkinson's disease and neurodegenerative dementia: A nationally representative study. Res Social Adm Pharm. 2016 Jul-Aug; 12(4):604-13.
Score: 0.028
-
The definition and prevalence of pediatric psychotropic polypharmacy. Psychiatr Serv. 2011 Dec; 62(12):1450-5.
Score: 0.021
-
Drug use trends for arthritis and other rheumatic conditions and effect of patient's age on treatment choice. N C Med J. 2011 Nov-Dec; 72(6):432-8.
Score: 0.021
-
Risk of falls and fractures in older adults using antipsychotic agents: a propensity-matched retrospective cohort study. Drugs Aging. 2010 Oct 01; 27(10):815-29.
Score: 0.020
-
Risk of cerebrovascular adverse events in older adults using antipsychotic agents: a propensity-matched retrospective cohort study. J Clin Psychiatry. 2010 Jun; 71(6):689-98.
Score: 0.019
-
Concomitant antipsychotic prescribing in US outpatient settings. Res Social Adm Pharm. 2009 Sep; 5(3):234-41.
Score: 0.017
-
Hypertension management in outpatient visits by diabetic patients. Res Social Adm Pharm. 2008 Sep; 4(3):284-91.
Score: 0.017
-
Clinically important potential drug-drug interactions in outpatient settings. Res Social Adm Pharm. 2007 Dec; 3(4):426-37.
Score: 0.016
-
Pharmacotherapy with atomoxetine for US children and adolescents. Ann Clin Psychiatry. 2007 Jul-Sep; 19(3):175-80.
Score: 0.016
-
Patterns and determinants of antipsychotic prescribing in children and adolescents, 2003-2004. Curr Med Res Opin. 2007 Jan; 23(1):49-56.
Score: 0.015
-
Patients' willingness to pay for naloxone: A national cross-sectional survey of prescription opioid users with chronic pain in the United States. J Am Pharm Assoc (2003). 2024 May-Jun; 64(3):102062.
Score: 0.012
-
Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis. Exp Neurol. 2023 01; 359:114238.
Score: 0.011
-
Autonomous ambulatory care by nurse practitioners and physician assistants in office-based settings. J Allied Health. 2001; 30(3):153-9.
Score: 0.010
-
Utilization of ambulatory care services caused by adverse effects of medications in the United States. Manag Care Interface. 2000 Apr; 13(4):70-5.
Score: 0.009
-
Opioid-induced emesis among hospitalized nonsurgical patients: effect on pain and quality of life. J Pain Symptom Manage. 1999 Oct; 18(4):280-8.
Score: 0.009
-
Drug-related-injury visits to hospital emergency departments. Am J Health Syst Pharm. 1998 Jun 01; 55(11):1158-61.
Score: 0.008
-
Outcomes associated with Clostridium difficile infection in patients with chronic liver disease. Epidemiol Infect. 2018 07; 146(9):1101-1105.
Score: 0.008
-
Louisiana hospital pharmacists' membership in ASHP. Am J Health Syst Pharm. 1996 Nov 15; 53(22):2737-9.
Score: 0.007
-
Application of the nonlinear Blinder-Oaxaca decomposition to study racial/ethnic disparities in antiobesity medication use in the United States. Res Social Adm Pharm. 2013 Jan-Feb; 9(1):13-26.
Score: 0.005